And also CYP treatment should be cheaper and more scalable as it is iPSC based and does not require regular new donors like MSB
Why Cynata's GvHD Treatment Might Not Need a Phase Two Trial for FDA Approval, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.015(9.09%) |
Mkt cap ! $40.67M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.5¢ | $29.91K | 170.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35924 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 27622 | 2 |
View Market Depth
| Last trade - 15.57pm 28/07/2025 (20 minute delay) ? |
| CYP (ASX) Chart |